0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Epigenomics"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
Genome Editing in Drug Discovery. Edition No. 1 - Product Thumbnail Image

Genome Editing in Drug Discovery. Edition No. 1

  • Book
  • April 2022
  • 352 Pages
EUR$218USDGBP
Precision Medicine in Oncology. Edition No. 1 - Product Thumbnail Image

Precision Medicine in Oncology. Edition No. 1

  • Book
  • October 2020
  • 288 Pages
EUR$222USDGBP
EUR$182USDGBP
Toxicology and Epigenetics. Edition No. 1 - Product Thumbnail Image

Toxicology and Epigenetics. Edition No. 1

  • Book
  • September 2012
  • 688 Pages
EUR$265USDGBP
EUR$261USDGBP
Medical and Health Genomics - Product Thumbnail Image

Medical and Health Genomics

  • Book
  • June 2016
EUR$118USDGBP
EUR$269USDGBP
EUR$173USDGBP
EUR$173USDGBP
EUR$173USDGBP
EUR$96USDGBP
Loading Indicator

Epigenomics is a field of genomics that studies the regulation of gene expression through chemical modifications of DNA and its associated proteins. It focuses on the heritable changes in gene expression that occur without changes in the underlying DNA sequence. These modifications, known as epigenetic marks, are involved in a variety of biological processes, including development, aging, and disease. Epigenomics research has been used to identify biomarkers for cancer diagnosis and prognosis, as well as to develop new therapeutic strategies. It has also been used to study the effects of environmental factors on gene expression, such as nutrition, stress, and exposure to toxins. The epigenomics market is expected to grow significantly in the coming years, driven by increasing investments in research and development, technological advancements, and the growing prevalence of cancer and other diseases. Some companies in the epigenomics market include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, Merck KGaA, and Oxford Nanopore Technologies. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more